<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04008004</url>
  </required_header>
  <id_info>
    <org_study_id>EDP 514-001</org_study_id>
    <nct_id>NCT04008004</nct_id>
  </id_info>
  <brief_title>A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)</brief_title>
  <official_title>A Phase 1a/1b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of EDP 514 in Healthy Subjects (Part 1), and Antiviral Activity in Nucleos(t)Ide Reverse Transcriptase Inhibitor (NUC)-Suppressed Patients With Chronic Hepatitis B Virus Infection (Part 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enanta Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmaceutical Research Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Enanta Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part 1 is a randomized, double-blind, placebo-controlled study. It will assess the safety,&#xD;
      tolerability, and pharmacokinetics of single and multiple orally administered doses of&#xD;
      EDP-514 in healthy adult subjects.&#xD;
&#xD;
      Part 2 is randomized, double -blind, placebo-controlled study including subjects with&#xD;
      Hepatitis B Virus. It will assess the safety, tolerability, pharmacokinetics and antiviral&#xD;
      activity of 28 Days of orally administered doses of EDP-514 in nucleos(t)ide reverse&#xD;
      transcriptase inhibitor (NUC)-Suppressed Patients with Chronic Hepatitis B Virus Infection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 consists of two phases planned in healthy subjects:&#xD;
&#xD;
      The first phase assesses single ascending doses for EDP-514 (active drug or placebo) in&#xD;
      healthy subjects. A &quot;fasted&quot; and &quot;fed&quot; two-part cohort will also assess food effect.&#xD;
&#xD;
      The second phase assesses multiple ascending doses (active drug or placebo) for 14 days in&#xD;
      healthy subjects.&#xD;
&#xD;
      Each cohort within each phase will enroll a total of 8 subjects who will be randomized to&#xD;
      receive EDP-514 or placebo. The cohort assessing food effect will enroll 10 subjects&#xD;
      randomized to receive EDP-514 or placebo.&#xD;
&#xD;
      Part 2 assesses multiple ascending doses EDP-514 (active drug or placebo) for 28 days in&#xD;
      nucleos(t)ide reverse transcriptase inhibitor (NUC)-Suppressed Patients with Chronic&#xD;
      Hepatitis B Virus Infection.&#xD;
&#xD;
      Each cohort in Part 2 will enroll a total of 8 subjects who will be randomized to receive&#xD;
      EDP-514 or placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measured by adverse events</measure>
    <time_frame>Up to 8 Days in HV SAD Cohorts</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety measured by adverse events</measure>
    <time_frame>Up to 21 Days in HV MAD Cohorts</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety measured by adverse events</measure>
    <time_frame>Up to 56 Days in HBV MAD Cohorts</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of EDP-514</measure>
    <time_frame>Up to 6 Days in HV SAD Cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of EDP-514</measure>
    <time_frame>Up to 6 Days in HV SAD Cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of EDP-514</measure>
    <time_frame>Up to 18 Days in HV MAD Cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of EDP-514</measure>
    <time_frame>Up to 18 Days in HV MAD Cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of EDP-514</measure>
    <time_frame>Up to 28 Days in HBV MAD Cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of EDP-514</measure>
    <time_frame>Up to 28 Days in HBV MAD Cohorts</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Chronic HBV Infection</condition>
  <arm_group>
    <arm_group_label>EDP-514 HV SAD Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EDP-514 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6 orally, once daily in one single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-514 HV MAD Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EDP-514 Dose 1, Dose 2 and Dose 3 orally, once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-514 HV SAD Placebo Cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, orally, once daily in one single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-514 HV MAD Placebo Cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, orally, once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-514 HBV MAD Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EDP-514 Dose 1, Dose 2 and Dose 3 orally, once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-514 HBV MAD Placebo Cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, orally, once daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-514</intervention_name>
    <description>Oral Capsule; Subjects will receive either a single dose of EDP-514 on Day 1 only (SAD HV), once daily dosing of EDP-514 starting on Day 1 through Day 14 (MAD HV) or once daily dosing of EDP-514 starting on Day 1 through Day 28 (MAD HBV).</description>
    <arm_group_label>EDP-514 HBV MAD Cohorts</arm_group_label>
    <arm_group_label>EDP-514 HV MAD Cohorts</arm_group_label>
    <arm_group_label>EDP-514 HV SAD Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match EDP-514</description>
    <arm_group_label>EDP-514 HBV MAD Placebo Cohort</arm_group_label>
    <arm_group_label>EDP-514 HV MAD Placebo Cohort</arm_group_label>
    <arm_group_label>EDP-514 HV SAD Placebo Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Part 1 (HV Population):&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  An informed consent document signed and dated by the subject.&#xD;
&#xD;
          -  Healthy male and female subjects of any ethnic origin between the ages of 18 and 65&#xD;
             years, inclusive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically relevant evidence or history of illness or disease.&#xD;
&#xD;
          -  Pregnant or nursing females.&#xD;
&#xD;
          -  History of febrile illness within 7 days prior to the first dose of study drug or&#xD;
             subjects with evidence of active infection.&#xD;
&#xD;
          -  A positive urine drug screen at screening or Day -1.&#xD;
&#xD;
          -  Current tobacco smokers or use of tobacco within 3 months prior to screening.&#xD;
&#xD;
          -  Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy).&#xD;
&#xD;
          -  History of regular alcohol consumption.&#xD;
&#xD;
          -  Receipt of any vaccine, an investigational agent or biological product within 28 days&#xD;
             or 5 times the t½, whichever one is longer, prior to first dose. This includes agents&#xD;
             administered during clinical trial participation.&#xD;
&#xD;
        Part 2 (HBV Population):&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  An informed consent document signed and dated by the subject.&#xD;
&#xD;
          -  Healthy male and female subjects of any ethnic origin between the ages of 18 and 70&#xD;
             years, inclusive&#xD;
&#xD;
          -  HBV DNA levels:&#xD;
&#xD;
               -  A Screening HBV DNA level in serum/plasma that is &lt;LLOQ and&#xD;
&#xD;
               -  No HBV DNA serum/plasma test values ≥LLOQ over the previous 12 months (using an&#xD;
                  approved test)&#xD;
&#xD;
          -  CHB subjects must have been on their prescribed HBV NUC treatment with no change in&#xD;
             regimen for 12 months prior to Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A documented prior diagnosis of cirrhosis&#xD;
&#xD;
          -  Pregnant or nursing females&#xD;
&#xD;
          -  Coinfection with human immunodeficiency virus (HIV), HCV, HDV, HAV, or HEV&#xD;
&#xD;
          -  Chronic liver disease of a non-HBV etiology; coexisting liver or biliary diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enanta Pharmaceuticals, Inc</last_name>
    <role>Study Director</role>
    <affiliation>Enanta Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Enanta Pharmaceuticals, Inc</last_name>
    <phone>+1 617 607 0705</phone>
    <email>nadda@enanta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southern California GI and Liver Centers</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarek Hassanein, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven-Huy Han, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tuan Nguyen Md Gastroenterology &amp; Hepatology (Tuan Nguyen, M.D., Inc.)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tuan Nguyen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Lalezari, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Martin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pharmaceutical Research Associates, Inc.</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Associates - Catonsville</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natarajan Ravendhran</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Dieterich</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>American Research Corporation</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Lawitz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish Organ Transplant and Liver Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Goldman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Coffin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Institute of Research Institute</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alnoor Ramji, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Feld</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanne-Marie Giard</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 2, 2019</study_first_submitted>
  <study_first_submitted_qc>July 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>&quot;First-in-Human&quot;</keyword>
  <keyword>Single Ascending Dose</keyword>
  <keyword>Multiple Ascending Dose</keyword>
  <keyword>hepatitis B virus</keyword>
  <keyword>HBV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Herpesviridae Infections</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

